The trial is being conducted in seven centers throughout Sweden and will focus on exploring the safety and tolerability of PBT2. The phase IIa study will also examine its effects on the mechanism and progression of the disease, investigating both central and peripheral biomarkers of Alzheimer’s disease as well as cognition.
The efficacy endpoints will be PBT2’s effect on cerebrospinal fluid (CSF) and plasma biomarkers as well as cognition. Results are expected to be announced in the fourth quarter of 2007.
“If this drug can be shown to move any of these biomarkers, it will demonstrate the drug’s potential as a mechanistic treatment for Alzheimer’s disease,” said principal investigator for the trial Professor Lars Lannfelt.